BR112021016142A2 - Uso de agonistas de ppar-delta no tratamento de miopatia mitocondrial - Google Patents

Uso de agonistas de ppar-delta no tratamento de miopatia mitocondrial

Info

Publication number
BR112021016142A2
BR112021016142A2 BR112021016142A BR112021016142A BR112021016142A2 BR 112021016142 A2 BR112021016142 A2 BR 112021016142A2 BR 112021016142 A BR112021016142 A BR 112021016142A BR 112021016142 A BR112021016142 A BR 112021016142A BR 112021016142 A2 BR112021016142 A2 BR 112021016142A2
Authority
BR
Brazil
Prior art keywords
treatment
ppar
mitochondrial myopathy
delta agonists
agonists
Prior art date
Application number
BR112021016142A
Other languages
English (en)
Inventor
Alex Dorenbaum
Colin O'carroll
Lynn Purkins
Niall O'donnell
Original Assignee
Reneo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneo Pharmaceuticals Inc filed Critical Reneo Pharmaceuticals Inc
Publication of BR112021016142A2 publication Critical patent/BR112021016142A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de agonistas de ppar-delta no tratamento de miopatia mitocondrial. é descrito no presente documento o uso de agonistas de ppard no tratamento de miopatia mitocondrial.
BR112021016142A 2019-02-20 2020-02-20 Uso de agonistas de ppar-delta no tratamento de miopatia mitocondrial BR112021016142A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962808137P 2019-02-20 2019-02-20
PCT/US2020/019059 WO2020172421A1 (en) 2019-02-20 2020-02-20 Use of ppar-delta agonists in the treatment of mitochondrial myopathy

Publications (1)

Publication Number Publication Date
BR112021016142A2 true BR112021016142A2 (pt) 2022-01-04

Family

ID=72144463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016142A BR112021016142A2 (pt) 2019-02-20 2020-02-20 Uso de agonistas de ppar-delta no tratamento de miopatia mitocondrial

Country Status (14)

Country Link
US (1) US20220117972A1 (pt)
EP (1) EP3927718A4 (pt)
JP (1) JP2022523645A (pt)
KR (1) KR20210134348A (pt)
CN (1) CN113710683A (pt)
AU (1) AU2020224129A1 (pt)
BR (1) BR112021016142A2 (pt)
CA (1) CA3127470A1 (pt)
IL (1) IL285500A (pt)
MA (1) MA55040A (pt)
MX (1) MX2021009938A (pt)
SG (1) SG11202108926YA (pt)
TW (1) TW202045152A (pt)
WO (1) WO2020172421A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163240A1 (en) * 2019-02-04 2020-08-13 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of fatty acid oxidation disorders (faod)
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
KR20240037940A (ko) * 2021-06-02 2024-03-22 아스테라스 세이야쿠 가부시키가이샤 Ppar 작용제 화합물의 사용 방법 및 이의 약학 조성물
JPWO2023282306A1 (pt) * 2021-07-06 2023-01-12
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
CN114457114B (zh) * 2022-03-07 2023-07-14 中国人民解放军空军军医大学 一种Fars2基因条件性敲除动物模型的构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110396A2 (en) * 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
WO2007071766A2 (en) * 2005-12-22 2007-06-28 Transtech Pharma Phenoxy acetic acids as ppar delta activators
EP3756661A1 (en) * 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2020163240A1 (en) * 2019-02-04 2020-08-13 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of fatty acid oxidation disorders (faod)

Also Published As

Publication number Publication date
KR20210134348A (ko) 2021-11-09
CA3127470A1 (en) 2020-08-27
EP3927718A4 (en) 2022-12-07
JP2022523645A (ja) 2022-04-26
EP3927718A1 (en) 2021-12-29
US20220117972A1 (en) 2022-04-21
AU2020224129A1 (en) 2021-10-07
SG11202108926YA (en) 2021-09-29
TW202045152A (zh) 2020-12-16
CN113710683A (zh) 2021-11-26
WO2020172421A1 (en) 2020-08-27
IL285500A (en) 2021-09-30
MX2021009938A (es) 2021-10-13
MA55040A (fr) 2021-12-29

Similar Documents

Publication Publication Date Title
BR112021016142A2 (pt) Uso de agonistas de ppar-delta no tratamento de miopatia mitocondrial
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2018000293A1 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015003512A1 (es) Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112015030399A2 (pt) derivados heterocíclicos e uso dos mesmos
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112017023432A2 (pt) Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
CL2016001746A1 (es) Derivados de hidroxi formamida y sus usos
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CY1122504T1 (el) Τροφη για πτηνα και ειδικοτερα τροφη για πουλερικα, που περιλαμβανει συνθετικα καψαϊκινοειδη παραγωγα και χρηση της εν λογω τροφης για σκοπους προφυλαξης ή αντιμετωπισης λοιμωξης απο σαλμονελα
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
CY1121957T1 (el) Χρηση της αδελμιδρολης στη θεραπεια επιθηλιακων δυσλειτουργιων

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 21/02 , C07H 21/04 , C07K 16/00 , C07K 16/40 , C12N 15/63 , C12P 21/08

Ipc: A61K 31/5375 (2006.01), C07H 21/04 (2006.01), C07K